12/19/14 - 04:16 PM EST
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.READ FULL POST
12/19/14 - 08:25 AM EST
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.READ FULL POST
12/16/14 - 11:20 AM EST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.READ FULL POST
12/15/14 - 09:23 AM EST
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.READ FULL POST
12/03/14 - 04:01 PM EST
The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.READ FULL POST
12/03/14 - 01:31 PM EST
Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.READ FULL POST
12/02/14 - 04:34 PM EST
Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.READ FULL POST
12/01/14 - 11:37 AM EST
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.READ FULL POST
11/24/14 - 09:39 AM EST
The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.READ FULL POST
11/19/14 - 01:25 PM EST
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.